Nanoscope Therapeutics to Attend Boston Tech Conference

Executives will present on gene therapy developments at the Advanced Therapies USA 2026 meeting this November.

Updated on Oct. 31, 2026 in Biotech

Nanoscope Therapeutics to Attend Boston Tech Conference

Live Poll

Are new gene therapies for blindness moving toward public availability quickly enough?

Nanoscope Therapeutics leadership will head to Boston on November 4-5, 2026, to participate in the Advanced Therapies USA 2026 conference. The team will deliver presentations on the company's optogenetic gene therapy developments during the two-day event.

Why it matters

The company's presence at the conference serves to address the practical challenges of transitioning advanced gene therapies from clinical research to patient access. Leaders will discuss regulatory, commercial, and market pathways for their pipeline candidates.

Nanoscope Therapeutics is developing MOGENRY, an optogenetic gene therapy, and is preparing for a 2026 Phase 3 trial. The firm also anticipates beginning a Phase 2 program for MCO in geographic atrophy within the same year.

The players

Nanoscope Therapeutics

A Dallas-based biotechnology company focused on the development of gene therapies for retinal degeneration.

The details

Nanoscope Therapeutics executives will join keynote panels at the Hynes Convention Center to detail scientific and market access strategies for their therapies. The Dallas-based firm is currently seeking regulatory approval for its MCO-010 treatment, which has earned FDA Fast Track and Orphan Drug status.

November 4, 2026: Leadership panels and presentations occur in Boston.
November 5, 2026: Leadership panels and presentations occur in Boston.

The Tech Race

This move reflects the competitive drive to bring optogenetic gene therapies to market ahead of emerging rivals in the ophthalmology space. The company is transitioning its R&D focus from early-phase trials to broad registrational efforts to secure its position in the biotech sector.

Investors and patients tracking the development of retinal degeneration treatments can gain insight into clinical timelines through the company's conference disclosures. These updates provide clarity on the projected availability of emerging gene therapy options.

The takeaway

Advancing novel gene therapies requires balancing scientific innovation with clear commercial and regulatory strategies. Staying informed on these conferences helps stakeholders understand the realistic timelines for new medical treatments reaching the public.

What happens next

Nanoscope Therapeutics is scheduled to initiate a Phase 3 registrational trial in 2026 and a Phase 2 program for MCO in geographic atrophy later that same year.